Home > Journals > Minerva Cardiology and Angiology > Past Issues > Minerva Cardiology and Angiology 2021 June;69(3) > Minerva Cardiology and Angiology 2021 June;69(3):291-8

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

ORIGINAL ARTICLE   

Minerva Cardiology and Angiology 2021 June;69(3):291-8

DOI: 10.23736/S2724-5683.20.05229-9

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Instantaneous wave-free ratio-guided revascularization of non-culprit lesion in patients with ST-segment elevation myocardial infarction and multivessel coronary disease: design and rationale of the WAVE Registry

Carmine MUSTO 1 , Annunziata NUSCA 2, Giuseppe BIONDI-ZOCCAI 3, 4, Francesco DE FELICE 1, Massimiliano SCAPPATICCI 5, Marco S. NAZZARO 1, Michele M. VISCUSI 2, Andrea CECCACCI 1, Francesco VERSACI 4, 5

1 Interventional Cardiology Unit, San Camillo Hospital, Rome, Italy; 2 Cardiac Sciences Unit, Campus Bio-Medico University, Rome, Italy; 3 Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University, Latina, Italy; 4 Mediterranea Cardiocentro, Naples, Italy; 5 Coronary Intensive Care Unit, Department of Cardiology and Hemodynamics, Santa Maria Goretti Hospital, Latina, Italy



BACKGROUND: The optimal management of patients with ST-elevation acute coronary syndromes and multivessel coronary artery disease is challenging. There is a growing body of evidence supporting invasive functional evaluation of multivessel disease with FFR or iFR, which it has been added to the literature. In this regard, the WAVE Study recently demonstrated the diagnostic accuracy of instantaneous wave-free ratio (iFR) functional assessment of non-culprit lesions in multivessel patients with STEMI. However, no studies have still verified the long-term clinical impact of an iFR-guided revascularization in this setting of patients.
METHODS: Patients undergoing primary PCI for STEMI and presenting multivessel disease will be enrolled. After the treatment of the culprit lesion, an iFR-guided functional assessment of non-culprit lesions will be done if iFR≤0.89 PCI will be performed during the index procedure or staged. Conversely, iFR>0.89 will direct the patient towards a conservative approach.
RESULTS: The study start date was May 1, 2018. The enrollment phase was completed on March 30, 2020. The primary endpoint is the occurrence of target lesion failure (TLF), a composite of cardiovascular death, non-fatal myocardial infarction, and ischemia-driven revascularization of the vessel previously assessed with iFR. Secondary endpoints include MACE (cardiovascular death, non-fatal MI, any revascularization).
CONCLUSIONS: The aim of the present study was to evaluate the long-term clinical impact of an iFR-guided revascularization of the non-culprit lesions in STEMI patients with multivessel coronary artery disease.


KEY WORDS: Cardiology; Arteries; Infarction

top of page